Everett Harris & Co. CA Acquires 13,586 Shares of Novo Nordisk A/S $NVO

Everett Harris & Co. CA lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,407,366 shares of the company’s stock after acquiring an additional 13,586 shares during the quarter. Novo Nordisk A/S accounts for 3.9% of Everett Harris & Co. CA’s holdings, making the stock its 6th biggest position. Everett Harris & Co. CA owned approximately 0.14% of Novo Nordisk A/S worth $326,007,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Franklin Resources Inc. increased its stake in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors increased its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $310,199,000. Clear Street Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $56,378,000. Finally, Contrarius Group Holdings Ltd acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $47,337,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO opened at $41.05 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a market cap of $183.31 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The firm’s fifty day simple moving average is $41.71 and its two-hundred day simple moving average is $46.12.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities analysts anticipate that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on NVO shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its oral Wegovy pill has surpassed 3 million U.S. prescriptions in just over five months, suggesting very strong adoption and broadening use among patients who had not previously taken a GLP-1 drug.
• Positive Sentiment: Real-world data reportedly show Ozempic 2 mg performing competitively against Eli Lilly’s Mounjaro on glucose control and weight-loss outcomes, which supports Novo’s diabetes franchise. Article: Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
• Positive Sentiment: Novo also highlighted investigational zenagamtide data showing 14.6% weight loss in adults with type 2 diabetes, reinforcing optimism around its pipeline. Article: Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
• Positive Sentiment: The company continues its share repurchase program, which can help support earnings per share and signals management confidence. Article: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles framed Novo and Lilly as locked in a major race for the GLP-1 pill market ahead of Medicare coverage decisions, underscoring the long-term opportunity but also the competitive risk. Article: Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
• Negative Sentiment: Eli Lilly’s oral GLP-1 pill reportedly outperformed rival therapies in late-stage diabetes trials, highlighting the competitive threat facing Novo Nordisk. Article: LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
• Negative Sentiment: Investors also appeared disappointed that Novo’s ADA conference updates did not materially improve the company’s near-term competitive outlook, contributing to the stock’s weakness. Article: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.